Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models

被引:5
|
作者
Masui, Kenichi [1 ,2 ]
Ishigaki, Sayaka [2 ,3 ]
Tomita, Atsuko [2 ]
Otake, Hiroshi [1 ]
机构
[1] Showa Univ, Sch Med, Dept Anesthesiol, Shinagawa Ku, Hatanodai 1-5-8, Tokyo 1428666, Japan
[2] Natl Def Med Coll, Dept Anesthesiol, Tokorozawa, Saitama 3598513, Japan
[3] Self Def Force Yokosuka Hosp, Dept Anesthesiol, Yokosuka, Kanagawa 2370071, Japan
关键词
Neuromuscular blockade; Rocuronium; Pharmacodynamics; TARGET-CONTROLLED INFUSION; NEUROMUSCULAR BLOCKADE; BROMIDE ORG-9426; TIME-COURSE; BOLUS; ANESTHESIA; HALOTHANE;
D O I
10.1007/s00540-018-2543-3
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Purpose Equilibration rate constant is necessary to calculate effect-site concentration, which is useful to control drug effect. We developed pharmacodynamic models for published five compartmental pharmacokinetic models published by Wierda, Szenohradszky, Cooper, Alvarez-Gomez, and McCoy. Methods We used 3848 train-of-four ratios from 15 male and nine female patients (21-76 years; 44-93 kg body weight; 148-181 cm height; and 17.3-29.8 kg/m(2) body mass index) as pharmacodynamic measures, which were collected at the start of 0.6 mg/kg rocuronium administration until the end of the surgery. Effect compartment was assumed to be connected to central compartment of the pharmacokinetic model with equilibration rate constant (k(e0)). Sigmoid E-max model was fitted to describe the relationship between train-of-four ratio and effect-site concentration. Age, sex, and body mass index were assessed as possible covariates of the following model parameters: k(e0), effect-site concentration for half of maximum effect, and the steepness of the effect-site concentration versus effect relationship. Results The duration of neuromuscular monitoring was 69 (37-129) [median (range)] min. All pharmacodynamic models included age and three included sex as significant covariates. K-e0 values ranged between 0.0820 and 0.247 depending on the pharmacokinetic model. The time-courses of the effect-site concentration were similar among the pharmacodynamic models for Wierda, Cooper, and Alvarez-Gomez pharmacokinetic models, which were lower than that for the Szenohradszky pharmacokinetic model. Conclusion Each pharmacodynamic model with the corresponding pharmacokinetic model can be described the time course of rocuronium effect appropriately. The required effect-site concentration of rocuronium for a pharmacodynamic effect was depending on the applied models.
引用
收藏
页码:709 / 716
页数:8
相关论文
共 50 条
  • [21] Commentary: Stochastic phenomena in pharmacokinetic, pharmacodynamic, and pharmacogenomic models
    Ronald A. Siegel
    Murali Ramanathan
    The AAPS Journal, 7
  • [22] Animal models in the pharmacokinetic/pharmacodynamic evaluation of antimicrobial agents
    Zhao, Miao
    Lepak, Alexander J.
    Andes, David R.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (24) : 6390 - 6400
  • [23] PHARMACOKINETIC AND PHARMACODYNAMIC DATA AND MODELS IN CLINICAL-TRIALS
    STEIMER, JL
    EBELIN, ME
    VANBREE, J
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1993, 18 (01) : 61 - 76
  • [24] An Approach for Identifiability of Population Pharmacokinetic-Pharmacodynamic Models
    Shivva, V.
    Korell, J.
    Tucker, I. G.
    Duffull, S. B.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2013, 2 (06):
  • [25] Exploring inductive linearization in population pharmacokinetic and pharmacodynamic models
    Fidler, Matt
    Xiong, Yuan
    Schoemaker, Rik
    Wilkins, Justin
    Trame, Mirjam N.
    Post, Teun
    Hooijmakers, Richard
    Wang, Wenping
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S116 - S116
  • [26] Sensitivity analysis of pharmacodynamic parameters in pharmacodynamic models
    Guang Wu
    European Journal of Drug Metabolism and Pharmacokinetics, 2001, 26 : 59 - 63
  • [27] Sensitivity analysis of pharmacodynamic parameters in pharmacodynamic models
    Wu, G
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2001, 26 (1-2) : 59 - 63
  • [28] Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic Pharmacodynamic Models
    Agoram, B.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (02):
  • [29] Pharmacokinetic/Pharmacodynamic Models of an Alzheimer?s Drug, Donepezil, in Rats
    Kiriyama, Akiko
    Kimura, Shunsuke
    Yamashita, Shugo
    DRUG METABOLISM AND DISPOSITION, 2023, 51 (03) : 329 - 337
  • [30] Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check
    Yano, Y
    Beal, SL
    Sheiner, LB
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (02) : 171 - 192